Miles Capital Inc. trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,712 shares of the biopharmaceutical company’s stock after selling 390 shares during the quarter. Miles Capital Inc.’s holdings in Gilead Sciences were worth $826,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in GILD. Pictet Asset Management Ltd. boosted its position in shares of Gilead Sciences by 23.5% during the second quarter. Pictet Asset Management Ltd. now owns 4,378,155 shares of the biopharmaceutical company’s stock worth $295,788,000 after buying an additional 832,194 shares during the period. Westwood Holdings Group Inc. purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at $447,000. Point72 Asset Management L.P. purchased a new position in shares of Gilead Sciences during the second quarter worth about $682,000. CSat Investment Advisory L.P. grew its stake in Gilead Sciences by 2,545.6% during the 2nd quarter. CSat Investment Advisory L.P. now owns 1,508 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 1,451 shares during the last quarter. Finally, Coldstream Capital Management Inc. lifted its stake in Gilead Sciences by 4.2% in the second quarter. Coldstream Capital Management Inc. now owns 7,049 shares of the biopharmaceutical company’s stock valued at $476,000 after buying an additional 285 shares during the last quarter. Hedge funds and other institutional investors own 79.27% of the company’s stock.
A number of equities analysts have recently issued reports on GILD shares. Guggenheim lowered shares of Gilead Sciences from a “buy” rating to a “neutral” rating in a research report on Tuesday. ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Bank of America assumed coverage on Gilead Sciences in a report on Wednesday, October 16th. They issued a “neutral” rating and a $70.00 target price for the company. Oppenheimer upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating in a research report on Friday, January 3rd. Finally, Wells Fargo & Co set a $81.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Friday, October 25th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $78.91.
In other Gilead Sciences news, EVP Brett A. Pletcher sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $66.85, for a total value of $1,002,750.00. Following the completion of the transaction, the executive vice president now directly owns 32,064 shares in the company, valued at $2,143,478.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Brett A. Pletcher sold 4,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $64.52, for a total value of $258,080.00. Following the completion of the transaction, the executive vice president now owns 23,921 shares of the company’s stock, valued at $1,543,382.92. The disclosure for this sale can be found here. In the last quarter, insiders have sold 45,622 shares of company stock worth $2,986,438. 0.20% of the stock is owned by company insiders.
GILD traded down $0.50 on Tuesday, reaching $62.48. The company’s stock had a trading volume of 3,070,347 shares, compared to its average volume of 6,060,166. Gilead Sciences, Inc. has a 1 year low of $60.89 and a 1 year high of $70.50. The business’s 50 day moving average is $65.63 and its 200 day moving average is $65.13. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.96 and a quick ratio of 2.87. The stock has a market cap of $78.95 billion, a price-to-earnings ratio of 29.89, a price-to-earnings-growth ratio of 3.83 and a beta of 1.11.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.74 by $0.01. Gilead Sciences had a return on equity of 37.50% and a net margin of 12.04%. The company had revenue of $5.60 billion for the quarter, compared to the consensus estimate of $5.61 billion. During the same period in the previous year, the business earned $1.84 EPS. Gilead Sciences’s revenue for the quarter was up .1% compared to the same quarter last year. As a group, research analysts forecast that Gilead Sciences, Inc. will post 6.63 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.03%. The ex-dividend date of this dividend was Thursday, December 12th. Gilead Sciences’s dividend payout ratio is presently 40.98%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Further Reading: The limitations of an equal weight rating
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.